West China Hospital, Sichuan University
四川大学华西医院
West China Hospital, Sichuan University is one of China's top-tier medical institutions, repeatedly named in partner content as a leading center for neurological research and clinical trials. Per BlueRun Ventures, it was among 13 top domestic neurosurgery hospitals that co-launched a multi-center clinical study with CAS-Ruiyi in August 2021 to establish normative data for motor and cognitive function in Chinese populations , with patient enrollment completed as of early 2023 . In a separate 5Y Capital piece, Huanyi Bio listed it among roughly 30 domestic and international research partners with which the company has built deep collaborations to accumulate clinical immunology data . Elsewhere's corpus does not cover its founding date, scale, or broader institutional profile beyond these research partnerships.
AI-generated — may contain errors, please verify.
Coverage
CereMediTech Successfully Completes Series A+ Funding Round | BlueRun Ventures
Building the "New Infrastructure" for Diagnosing and Treating Neurological Disorders
CereMediTech Completes Tens of Millions of Yuan in Series A Funding to Advance Intelligent Diagnosis and Treatment Infrastructure for Neurological Diseases | BlueRun Ventures
Intelligent Technology Solutions for Full-Spectrum Neurological Diseases
BlueRun Ventures Leads Pre-A Round Worth Tens of Millions of RMB for Zhongke Ruiyi | BlueRun Ventures
Building "New Infrastructure" for Neuroscience
5Y News|Vivace Therapeutics Announces Completion of Angel Round Raising Tens of Millions of RMB
Huanyi Bio announced the completion of an angel funding round of tens of millions of RMB, led by 5Y Capital.



